Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: A systematic review

Neuropsychiatric Disease and Treatment

Volumn 13, Issue , 2017, Pages 2285-2296

  Sajatovic, Martha ^a   DiBiasi, Faith ^b   Legacy, Susan N ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotics; Attitudes; Bipolar disorder; Systematic review

Indexed keywords

NEUROLEPTIC AGENT;

BIPOLAR DISORDER; CAREGIVER; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; HUMAN; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRESCRIPTION; PSYCHOEDUCATION; REVIEW; SYSTEMATIC REVIEW;

EID: 85028705503     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S139557     Document Type: Review

References (56)

1. Dell’Aglio JC Jr, Basso LA, Argimon II, Arteche A. Systematic review of the prevalence of bipolar disorder and bipolar spectrum disorders in population-based studies. Trends Psychiatry Psychother. 2013;35(2):99–105.
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
3. Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148(2–3):161–169.
4. Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. Epub 2016 Dec 10.
5. Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: a review. Psychiatr Danub. 2014;26(2):108–114.
6. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123(3):175–189.
7. Abilify® (aripiprazole) [prescribing information]. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2016.
8. Saphris® (asenapine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2015.
9. US Food and Drug Administration. Approval package for: application number NDA 20-592/S-006 Zyprexa oral tablets. 2000 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020592_S006_ZUPREXA_ORAL_TABS_AP.pdf. Accessed December 1, 2016.
10. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
11. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206.
12. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, second edition; 2002. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice:guidelines/guidelines/bipolar.pdf. Accessed July 21, 2016.
13. American Psychiatric Association. Guideline watch: practice guideline for the treatment of patients with bipolar disorder, second edition; 2005. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice:guidelines/guidelines/bipolar-watch.pdf. Accessed November 22, 2016.
14. Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord. 2016;18(2):174–182.
15. Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry. 2010;18(5):266–278.
16. Karanti A, Kardell M, Lundberg U, Landen M. Changes in mood stabilizer prescription patterns in bipolar disorder. J Affect Disord. 2016;195:50–56.
17. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–359.
18. Arvilommi P, Suominen K, Mantere O, Leppamaki S, Valtonen H, Isometsa E. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders–an 18-month prospective study. J Affect Disord. 2014;155:110–117.
19. Medina E, Salva J, Ampudia R, Maurino J, Larumbe J. Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. Patient Prefer Adherence. 2012;6:623–629.
20. Bauer M, Lecrubier Y, Suppes T. Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. Eur Psychiatry. 2008;23(3):169–177.
21. Campbell EC, DeJesus M, Herman BK, et al. A pilot study of antipsychotic prescribing decisions for acutely-Ill hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):246–251.
22. Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Am J Manag Care. 2014;20(2):e52–e60.
23. Vogt WB, Joyce G, Xia J, Dirani R, Wan G, Goldman DP. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Aff (Millwood). 2011;30(12):2346–2354.
24. Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry. 1985;30(4):246–248.
25. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol. 1995;10(Suppl 3):123–132.
26. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18(13):877–893.
27. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia–findings from an in vivo SPECT study. Schizophr Res. 2006;88(1–3):179–186.
28. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911–936.
29. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617–622.
30. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Ongur D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012;27(5):521–526.
31. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303–319.
32. Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry. 2010;12(5).
33. Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369–377.
34. Altamura AC, Armadoros D, Jaeger M, Kernish R, Locklear J, Volz HP. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Curr Med Res Opin. 2008;24(8):2271–2282.
35. Levin JB, Seifi N, Cassidy KA, et al. Comparing medication attitudes and reasons for medication nonadherence among three disparate groups of individuals with serious mental illness. J Nerv Ment Dis. 2014;202(11):769–773.
36. Strejilevich S, Garcia Bonetto G. Subjective responses to pharmacological treatments in bipolar patients. J Affect Disord. 2003;77(2):191–192.
37. Ventriglio A, Gentile A, Baldessarini RJ, et al. Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients. Eur Psychiatry. 2014;29(7):402–407.
38. Fagiolini A, Brugnoli R, Di Sciascio G, De Filippis S, Maina G. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother. 2015;16(5):727–737.
39. Goldberg JF, Freeman MP, Balon R, et al. The American Society of Clinical Psychopharmacology survey of psychopharmacologists’ practice patterns for the treatment of mood disorders. Depress Anxiety. 2015;32(8):605–613.
40. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.
41. Harvey NS. The development and descriptive use of the Lithium Attitudes Questionnaire. J Affect Disord. 1991;22(4):211–219.
42. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384–390.
43. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609–618.
44. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20(2):297–310.
45. Rofail D, Gray R, Gournay K. The development and internal consistency of the satisfaction with Antipsychotic Medication Scale. Psychol Med. 2005;35(7):1063–1072.
46. Hogan TP, Awad AG. Drug attitude inventory. In: Rush A, editor. Handbook of Psychiatric Measures. Arlington, VA: American Psychiatric Association Publishing; 2000.
47. Teter CJ, Falone AE, Bakaian AM, Tu C, Ongur D, Weiss RD. Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. Psychiatry Res. 2011;190(2–3):253–258.
48. Sajatovic M, Levin J, Fuentes-Casiano E, Cassidy KA, Tatsuoka C, Jenkins JH. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry. 2011;52(3):280–287.
49. Sajatovic M, Levin J, Tatsuoka C, et al. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder. Bipolar Disord. 2012;14(3):291–300.
50. Levin JB, Tatsuoka C, Cassidy KA, Aebi ME, Sajatovic M. Trajectories of medication attitudes and adherence behavior change in non-adherent bipolar patients. Compr Psychiatry. 2015;58:29–36.
51. Chang CW, Sajatovic M, Tatsuoka C. Correlates of attitudes towards mood stabilizers in individuals with bipolar disorder. Bipolar Disord. 2015;17(1):106–112.
52. Grover S, Chakrabarti S, Sharma A, Tyagi S. Attitudes toward psychotropic medications among patients with chronic psychiatric disorders and their family caregivers. J Neurosci Rural Pract. 2014;5(4):374–383.
53. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
54. Walpoth-Niederwanger M, Kemmler G, Grunze H, et al. Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers. Int Clin Psychopharmacol. 2012;27(5):256–266.
55. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
56. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12:181.